Cited by 1,145Schizophrenia research and treatmentPharmacology and Obesity TreatmentHIV-related health complications and treatments

The DOI matches its Crossref record; 130 of the 131 references it cites were found in a registry or an index.

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

De Hert, Marc, Detraux, Johan, van Winkel, Ruud, Yu, Weiping, Correll, Christoph U.·2012·Nature Reviews Endocrinology

DOI 10.1038/nrendo.2011.156

Open this paper in CoChat — free account

Abstract

Antipsychotic medications can induce cardiovascular and metabolic abnormalities (such as obesity, hyperglycemia, dyslipidemia and the metabolic syndrome) that are associated with an increased risk of type 2 diabetes mellitus and cardiovascular disease. Controversy remains about the contribution of individual antipsychotic drugs to this increased risk and whether they cause sudden cardiac death through prolongation of the corrected QT interval. Although some drug receptor-binding affinities correlate with specific cardiovascular and metabolic abnormalities, the exact pharmacological mechanisms underlying these associations remain unclear. Antipsychotic agents with prominent metabolic adverse effects might cause abnormalities in glucose and lipid metabolism via both obesity-related and obesity-unrelated molecular mechanisms. Despite existing guidelines and recommendations, many antipsychotic-drug-treated patients are not assessed for even the most easily measurable metabolic and cardiac risk factors, such as obesity and blood pressure. Subsequently, concerns have been raised over the use of these medications, especially pronounced in vulnerable pediatric patients, among whom their use has increased markedly in the past decade and seems to have especially orexigenic effects. This Review outlines the metabolic and cardiovascular risks of various antipsychotic medications in adults and children, defines the disparities in health care and finally makes recommendations for screening and monitoring of patients taking these agents.

Integrity signals

Registry

Crossref · 10.1038/nrendo.2011.156

Cites

130 of 130 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Bipolar Disorder
Yatham, L. N., & Malhi, G. S. (2011) · Oxford University Press eBooks · doi:10.1093/med/9780199562305.001.0001 · Cited by 3,515
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Systematic review and meta-analysis
Gillies, A. (2019) · CRC Press eBooks · doi:10.1201/9781315377315-19 · Cited by 2,876
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
A Population-Based Study
Christakis, D., Richards, J. A., Zimmerman, F. J., Garrison, M. M., Xu, D., & Yapanel, U. H. (2009) · Cited by 2,290
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., CHAITMAN, B. R., FROMER, M. A., Gregoratos, G., Klein, G. J., Myerburg, R. J., Quiñones, M. A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.010 · Cited by 1,975

Flagged first, then by citations

Show all 131 references

1 of the 131 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Citrome, L. Risk–benefit analysis of available treatments for schizophrenia. Psychiatric Times 1, 27–30 (2007).

Sorted by citations

Items 101–200 of 1,000

Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health
Stogios, N., Gdanski, A., Gerretsen, P., Chintoh, A. F., Graff-Guerrero, A., Rajji, T. K., Remington, G., Hahn, M. K., & Agarwal, S. M. (2021) · npj Schizophrenia · doi:10.1038/s41537-021-00151-6 · Cited by 98
The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review
Peuskens, J., Pani, L., Detraux, J., & De Hert, M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0157-3 · Cited by 350
Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population
Bly, M. J., Taylor, S. F., Dalack, G. W., Pop‐Busui, R., Burghardt, K. J., Evans, S. J., McInnis, M. G., Grove, T. B., Brook, R. D., Zöllner, S. K., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12160 · Cited by 106
Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes
Chen, J., Huang, X., Shao, R., Chen, C., & Deng, C. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00643 · Cited by 106
Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review
Hert, M. A. F. D., Peuskens, J., Sabbe, T., Mitchell, A. J., Stubbs, B., Neven, P., Wildiers, H. P. M. W., & Detraux, J. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12459 · Cited by 99
Metformin add‐on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial
Correll, C. U., Sikich, L., Reeves, G. M., Johnson, J. L., Keeton, C. P., Spanos, M., Kapoor, S., Bussell, K., Miller, L., Chandrasekhar, T., et al. (2020) · World Psychiatry · doi:10.1002/wps.20714 · Cited by 99
Importance of Early Weight Changes to Predict Long-Term Weight Gain During Psychotropic Drug Treatment
Vandenberghe, F., Gholam‐Rezaee, M., Saigí-Morgui, N., Delacrétaz, A., Choong, E., Solida-Tozzi, A., Kolly, S., Thonney, J., Gallo, S. F., Hedjal, A., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09358 · Cited by 98
Antipsychotics-induced metabolic alterations: Focus on adipose tissue and molecular mechanisms
Gonçalves, P., Araújo, J. R., & Martel, F. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.11.008 · Cited by 99
Treatment of adolescents with early-onset schizophrenia spectrum disorders
SCHIMMELMANN, B. G., Schmidt, S. J., Carbon, M., & Correll, C. U. (2013) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32835dcc2a · Cited by 94
Antipsychotic-Induced Metabolic and Cardiovascular Side Effects in Schizophrenia: A Novel Mechanistic Hypothesis
Scigliano, G., & Ronchetti, G. (2013) · CNS Drugs · doi:10.1007/s40263-013-0054-1 · Cited by 92
Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study
Rubio, J. M., Taipale, H. T., Tanskanen, A. J., Correll, C. U., Kane, J. M., & Tiihonen, J. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab063 · Cited by 92
A systematic review on automated clinical depression diagnosis
Mao, K., Wu, Y., & Chen, J. (2023) · npj Mental Health Research · doi:10.1038/s44184-023-00040-z · Cited by 106
Prescription Practices in the Treatment of First-Episode Schizophrenia Spectrum Disorders: Data From the National RAISE-ETP Study
Robinson, D. G., Schooler, N. R., John, M., Correll, C. U., Marcy, P., Addington, J., Brunette, M. F., Estroff, S. E., Mueser, K. T., Penn, D. L., et al. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13101355 · Cited by 93
Metabolic syndrome in subjects with bipolar disorder and major depressive disorder in a current depressive episode: Population-based study
Moreira, F. P., Jansen, K., Cardoso, T. D. A., Mondin, T. C., Magalhães, P. V. D. S., Kapczinski, F. P., Souza, L. D. D. M., da Silva, R. A., Oses, J. P., & Wiener, C. D. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.03.025 · Cited by 95
Repurposing psychiatric drugs as anti-cancer agents
Huang, J., Zhao, D., Liu, Z., & Liu, F. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.058 · Cited by 89
Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial
Fleischhacker, W. W., SIU, C. O., Bodén, R., Pappadopulos, E. A., Karayal, O. N., Kahn, R. S., & the EUFEST study group (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001241 · Cited by 92
Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series
Prasad, F., De, R., Korann, V., Chintoh, A. F., Remington, G., Ebdrup, B. H., Siskind, D., Knop, F. K., Vilsbøll, T., Fink-Jensen, A., et al. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231165169 · Cited by 88
Clozapine's Multiple Cellular Mechanisms: What Do We Know after More than Fifty Years? a Systematic Review and Critical Assessment of Translational Mechanisms Relevant for Innovative Strategies in Treatment-Resistant Schizophrenia
de Bartolomeis, A., Vellucci, L., Barone, A., Manchia, M., Luca, V. D., Iasevoli, F., & Correll, C. U. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108236 · Cited by 96
Reorganization of brain connectivity in obesity
Geha, P., Cecchi, G., Constable, R. T., Abdallah, C. G., & Small, D. M. (2016) · Human Brain Mapping · doi:10.1002/hbm.23462 · Cited by 85
Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia
Martin, W. F., Correll, C. U., Weiden, P. J., Jiang, Y., Pathak, S., DiPetrillo, L., Silverman, B. L., & Ehrich, E. W. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18030280 · Cited by 86
A Focused Review of the Metabolic Side-Effects of Clozapine
Yuen, J. W. Y., Kim, D. D., Procyshyn, R. M., Panenka, W. J., Honer, W. G., & Barr, A. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.609240 · Cited by 98
Brexpiprazole: so far so good
Das, S., Barnwal, P., Aruldhas, B. W., Mondal, S., & Saha, I. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315614739 · Cited by 84
A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
Citrome, L., McEvoy, J. P., Todtenkopf, M. S., McDonnell, D., & Weiden, P. J. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s209284 · Cited by 87
Choroid Plexus Enlargement and Allostatic Load in Schizophrenia
Zhou, Y., Huang, J., Zhang, P., Fan, F., Chen, S., Fan, H., Cui, Y., Luο, X., Tan, S., Wang, Z., et al. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sbz100 · Cited by 83
Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization
Blader, J. C., Pliszka, S. R., Kafantaris, V., Foley, C. A., Carlson, G. A., Crowell, J. A., Bailey, B. Y., Sauder, C. L., Daviss, W. B., Sinha, C., et al. (2020) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2019.12.009 · Cited by 87
Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study
Solmi, M., Tiihonen, J., Lähteenvuo, M., Tanskanen, A. J., Correll, C. U., & Taipale, H. T. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab087 · Cited by 82
Clozapine for the treatment of schizophrenia
Fakra, É., & Azorin, J. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.709235 · Cited by 82
Clozapine-Induced Cardiovascular Side Effects and Autonomic Dysfunction: A Systematic Review
Yuen, J. W. Y., Kim, D. D., Procyshyn, R. M., White, R. F., Honer, W. G., & Barr, A. M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00203 · Cited by 79
Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis
Correll, C. U., Ng‐Mak, D., Stafkey-Mailey, D., Farrelly, E., Rajagopalan, K., & Loebel, A. D. (2017) · Annals of General Psychiatry · doi:10.1186/s12991-017-0133-7 · Cited by 84
The effect of dietary and physical activity pattern on metabolic profile in individuals with schizophrenia: a cross-sectional study
Ratliff, J. C., Palmese, L. B., Reutenauer, E. L., Liskov, E., Grilo, C. M., & Tek, C. (2012) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2012.02.003 · Cited by 78
Insulin Resistance, Prediabetes, Metabolic Syndrome: What Should Every Pediatrician Know?
Ighbariya, A., & Weiss, R. (2018) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.2017.s005 · Cited by 78
Reducing excess mortality due to chronic disease in people with severe mental illness: Meta-review of health interventions
Baxter, A. J., Harris, M., Khatib, Y., Brugha, T. S., Bien, H., & Bhui, K. S. (2016) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.115.163170 · Cited by 82
Antipsychotics cardiotoxicity: What's known and what's next
Li, X., Tang, X.-R., & Li, L. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i10.736 · Cited by 80
Exploring the Relationship Between Schizophrenia and Cardiovascular Disease: A Genetic Correlation and Multivariable Mendelian Randomization Study
Veeneman, R. R., Vermeulen, J. M., Abdellaoui, A., Sanderson, E. C. M., Wootton, R. E., Tadros, R., Bezzina, C. R., Denys, D. A. J. P., Munafo, M. R., Verweij, K. J. H., et al. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab132 · Cited by 81
Corrected QT Changes During Antipsychotic Treatment of Children and Adolescents: A Systematic Review and Meta-Analysis of Clinical Trials
Jensen, K. G., Juul, K., Fink‐Jensen, A., Correll, C. U., & Pagsberg, A. K. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.10.002 · Cited by 78
Metformin and Berberine Prevent Olanzapine-Induced Weight Gain in Rats
Hu, Y., Young, A. J., Ehli, E. A., Nowotny, D., Davies, P. S., Droke, E. A., Soundy, T. J., & Davies, G. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093310 · Cited by 76
Reduced heart rate variability in schizophrenia and bipolar disorder compared to healthy controls
Quintana, D. S., Westlye, L. T., Kaufmann, T., Rustan, Ø. G., Brandt, C. L., Haatveit, B., Steen, N. E., & Andreassen, O. A. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12498 · Cited by 73
Second-Generation Antipsychotic Use in Children and Adolescents: A Six-Month Prospective Cohort Study in Drug-Naïve Patients
Arango, C., Giráldez, M., Merchán‐Naranjo, J., Baeza, I., Castro‐Fornieles, J., Alda, J.-A., Martínez‐Cantarero, C., Moreno, C., de Andrés, P., Cuerda, C., et al. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.08.009 · Cited by 75
Clinical Practice Guidelines for Management of Schizophrenia
Avasthi, A., Grover, S., Chakrabarti, S., & Kulhara, P. (2017) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.196972 · Cited by 75
Exercise Treatments for Psychosis: a Review
Mittal, V. A., Vargas, T., Osborne, K. J., Dean, D. J., Gupta, T., Ristanovic, I., Hooker, C. I., & Shankman, S. A. (2017) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-017-0112-2 · Cited by 86
The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study
Citrome, L., Ota, A., Nagamizu, K., Perry, P., Weiller, E., & Baker, R. A. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000123 · Cited by 74
Chronic Stress, Exercise and Cardiovascular Disease: Placing the Benefits and Risks of Physical Activity into Perspective
Franklin, B. A., Rusia, A., Haskin-Popp, C., & Tawney, A. M. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18189922 · Cited by 89
A Review of Acute Aerobic Exercise and Transcranial Direct Current Stimulation Effects on Cognitive Functions and Their Potential Synergies
Steinberg, F., Pixa, N. H., & Fregni, F. (2019) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2018.00534 · Cited by 75
Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics
Cernea, S., Dima, L., Correll, C. U., & Manu, P. (2020) · Drugs · doi:10.1007/s40265-020-01393-x · Cited by 76
Safety and tolerability of KarXT (xanomeline–trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia
Correll, C. U., Angelov, A. S., Miller, A., Weiden, P. J., & Brannan, S. K. (2022) · Schizophrenia · doi:10.1038/s41537-022-00320-1 · Cited by 72
Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials
Wu, R., Zhang, F.-Y., Gao, K.-M., Ou, J.-J., Shao, P., Jin, H., Guo, W.-B., Chan, P. K., & Zhao, J.-P. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.221 · Cited by 74
ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
Davis, R. E., & Correll, C. U. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1174577 · Cited by 72
Schizophrenia and type 2 diabetes mellitus
Mamakou, V., Thanopoulou, A. C., Gonidakis, F., Tentolouris, N., & Kontaxakis, V. P. (2018) · Psychiatriki · doi:10.22365/jpsych.2018.291.64 · Cited by 73
Diabetes and Mental Health
Robinson, D. J., Hanson, K., Jain, A. B., Kichler, J. C., Mehta, G., Melamed, O. C., Vallis, M., Bajaj, H. S., Barnes, T., Gilbert, J., et al. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.04.009 · Cited by 73
Trends in utilization and dosing of antipsychotic drugs in Scandinavia: Comparison of 2006 and 2016
Højlund, M., Pottegård, A., Johnsen, E., Kroken, R. A., Reutfors, J., Munk‐Jørgensen, P., & Correll, C. U. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13945 · Cited by 69
Epidemiology of diabetes mellitus
Mekala, K. C., & Bertoni, A. G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00004-6 · Cited by 88
Obese Schizophrenia Spectrum Patients Have Significantly Higher 10-Year General Cardiovascular Risk and Vascular Ages than Obese Individuals without Severe Mental Illness
Ratliff, J. C., Palmese, L. B., Reutenauer, E. L., Srihari, V. H., & Tek, C. (2012) · Psychosomatics · doi:10.1016/j.psym.2012.03.001 · Cited by 73
The Pharmacologic Management of Delirium in Children and Adolescents
Turkel, S. B., & Hanft, A. (2014) · Pediatric Drugs · doi:10.1007/s40272-014-0078-0 · Cited by 64
Higher mortality after myocardial infarction in patients with severe mental illness: a nationwide cohort study
Bodén, R., Molin, E., Jernberg, T., Kieler, H., Lindahl, B., & Sundström, J. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12329 · Cited by 68
Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options
Verhaegen, A. A., & Gaal, L. F. V. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0719-6 · Cited by 75
Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials
Højlund, M., Kemp, A. F., Haddad, P. M., Neill, J. C., & Correll, C. U. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00078-x · Cited by 67
Risk of suicide is insufficient warrant for coercive treatment for mental illness
Callaghan, S., Ryan, C. J., & Kerridge, I. (2013) · International Journal of Law and Psychiatry · doi:10.1016/j.ijlp.2013.06.021 · Cited by 65
Prevalence of the metabolic syndrome in patients with borderline personality disorder: results from a cross-sectional study
Kahl, K. G., Greggersen, W., Schweiger, U., Cordes, J., Correll, C. U., Frieling, H., Balijepalli, C., Lösch, C., & Moebus, S. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0339-2 · Cited by 68
GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats
Sharma, A. N., Ligade, S. S., Sharma, J. N., Shukla, P., Elased, K. M., & Lucot, J. B. (2014) · Metabolic Brain Disease · doi:10.1007/s11011-014-9591-7 · Cited by 66
Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia
Kane, J. M., Skuban, A., Hobart, M., Ouyang, J., Weiller, E., Weiss, C., & Correll, C. U. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.04.013 · Cited by 67
One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients
Svensson, C. K., Larsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Koyuncu, K., Schjerning, O., Nielsen, J., Ekstrøm, C. T., et al. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12982 · Cited by 66
Inflammatory Cytokines and Antipsychotic-Induced Weight Gain: Review and Clinical Implications
Fonseka, T. M., Müller, D. J., & Kennedy, S. H. (2016) · Complex Psychiatry · doi:10.1159/000441521 · Cited by 68
Non-invasive molecularly-specific millimeter-resolution manipulation of brain circuits by ultrasound-mediated aggregation and uncaging of drug carriers
Ozdas, M. S., Shah, A. S., Johnson, P. M., Patel, N., Marks, M., Yasar, T. B., Stalder, U., Bigler, L., von der Behrens, W., Sirsi, S. R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18059-7 · Cited by 63
Mortality and Its Determinants in People With Psychotic Disorder
Suvisaari, J., Partti, K., Perälä, J., Viertiö, S., Saarni, S. E., Lönnqvist, J. K., Saarni, S. I., & Härkänen, T. (2012) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31827ad512 · Cited by 66
Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis
Højlund, M., Köhler‐Forsberg, O., Gregersen, A. T., Rohde, C., Mellentin, A. I., Anhøj, S. J., Kemp, A. F., Fuglsang, N. F. B., Wiuff, A. C., Nissen, L., et al. (2024) · The Lancet Psychiatry · doi:10.1016/s2215-0366(24)00314-6 · Cited by 64
Metabolic disturbances associated with antipsychotic drug treatment in patients with schizophrenia: State-of-the-art and future perspectives
Chang, S.-C., Goh, K. K., & Lu, M. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i10.696 · Cited by 72
Frailty and severe mental illness: A systematic review and narrative synthesis
Pearson, E., Siskind, D. J., Hubbard, R. E., Gordon, E. H., Coulson, E. J., & Warren, N. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.01.014 · Cited by 63
Physical health outcomes and implementation of behavioural health homes: a comprehensive review
Murphy, K. A., Daumit, G. L., Stone, E. M., & McGinty, E. E. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1555153 · Cited by 60
Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatrists
Pisano, S., Catone, G., Veltri, S., Lanzara, V., Pozzi, M., Clementi, E., Iuliano, R., Riccio, M. P., Radice, S., Molteni, M., et al. (2016) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-016-0259-2 · Cited by 60
Physical health among people with serious mental illness in the face of COVID-19: Concerns and mitigation strategies
Melamed, O. C., Hahn, M., Agarwal, S. M., Taylor, V. H., Mulsant, B. H., & Selby, P. L. (2020) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2020.06.013 · Cited by 60
Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies
Correll, C. U., Skuban, A., Hobart, M., Ouyang, J., Weiller, E., Weiss, C., & Kane, J. M. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.04.012 · Cited by 58
Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia
Potkin, S. G., Kunovac, J. L., Silverman, B. L., Simmons, A., Jiang, Y., DiPetrillo, L., & McDonnell, D. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12769 · Cited by 57
Use of low‐dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator‐controlled cohort study
Højlund, M., Andersen, K., Ernst, M. T., Correll, C. U., & Hallas, J. (2022) · World Psychiatry · doi:10.1002/wps.21010 · Cited by 59
Psychosocial interventions for people with schizophrenia or psychosis on minimal or no antipsychotic medication: A systematic review
Cooper, R. E., Laxhman, N., Crellin, N. E., Moncrieff, J., & Priebe, S. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.05.020 · Cited by 62
Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders
Kraal, A. Z., Ward, K. M., & Ellingrod, V. L. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4358 · Cited by 57
Cannabinoid Receptor 2-Centric Molecular Feedback Loop Drives Necroptosis in Diabetic Heart Injuries
Gao, P., Cao, M., Jiang, X., Wang, X., Zhang, G., Tang, X., Yang, C., Komuro, I., Ge, J., Li, L., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059304 · Cited by 56
Genetics of Common Antipsychotic-Induced Adverse Effects
MacNeil, R. R., & Müller, D. J. (2016) · Complex Psychiatry · doi:10.1159/000445802 · Cited by 57
Drugs affecting body weight, body fat distribution, and metabolic function—mechanisms and possible therapeutic or preventive measures: an update.
Verhaegen, A. A., & Van Gaal, L. F. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00419-5 · Cited by 53
Antipsychotic-Induced Metabolic Syndrome: A Review
Akinola, S., Tardif, I., & Leclerc, J. (2023) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2023.0003 · Cited by 60
Combining aerobic exercise and repetitive transcranial magnetic stimulation to improve brain function in health and disease
Hendrikse, J. J., Kandola, A. A., Coxon, J. P., Rogasch, N. C., & Yücel, M. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.09.023 · Cited by 56
Excess Mortality from Mental, Neurological, and Substance Use Disorders in the Global Burden of Disease Study 2010
Charlson, F., Baxter, A. J., Dua, T., Degenhardt, L. J., Whiteford, H., & Vos, T. (2016) · World Bank, Washington, DC eBooks · doi:10.1596/978-1-4648-0426-7_ch3 · Cited by 55
Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson’s disease
Picillo, M., Erro, R., Santangelo, G., Pivonello, R., Longo, K., Pivonello, C., Vitale, C., Amboni, M., Moccia, M., Colao, A., et al. (2013) · Journal of Neurology · doi:10.1007/s00415-013-6851-0 · Cited by 56
The effectiveness of adjunct music therapy for patients with schizophrenia: A meta‐analysis
Jia, R., Liang, D., Yu, J., Lu, G., Wang, Z., Wu, Z., Huang, H., & Chen, C. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113464 · Cited by 58
Platelet parameters (PLT, MPV, P-LCR) in patients with schizophrenia, unipolar depression and bipolar disorder
Wysokiński, A., & Szczepocka, E. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.01.034 · Cited by 54
Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis
Stogios, N., Smith, E., Bowden, S., Tran, V., Asgariroozbehani, R., McIntyre, W. B., Remington, G. J., Siskind, D. J., Agarwal, S. M., & Hahn, M. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01163-7 · Cited by 57
Targeting Sleep Physiology to Modulate Glymphatic Brain Clearance
van Hattem, T., Verkaar, L., Krugliakova, E., Adelhöfer, N., Zeising, M., Drinkenburg, W. H. I. M., Claassen, J. A. H. R., Bódizs, R., Dresler, M., & Rosenblum, Y. (2024) · Physiology · doi:10.1152/physiol.00019.2024 · Cited by 57
Cardiometabolic Risk Indicators That Distinguish Adults with Psychosis from the General Population, by Age and Gender
Foley, D. L., Mackinnon, A. J., Watts, G. F., Shaw, J. E., Magliano, D. J., Castle, D. J., McGrath, J. J., Waterreus, A. J., Morgan, V. A., & Galletly, C. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082606 · Cited by 53
Biological treatment of Acute Agitation Or Aggression with Schizophrenia Or Bipolar Disorder in the Inpatient Setting
Correll, C. U., Yu, X., Xiang, Y., Kane, J. M., & Masand, P. S. (2017) · Annals of Clinical Psychiatry · doi:10.1177/104012371702900203 · Cited by 52
Emerging drugs for schizophrenia: an update
Köster, L.-S., Carbon, M., & Correll, C. U. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.958148 · Cited by 55
Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment
Stip, É., Lungu, O., Anselmo, K., Létourneau, G., Mendrek, A., Stip, B., Lipp, O., Lalonde, P., & Bentaleb, L. A. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.53 · Cited by 52
Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia
Nasser, A. F., Henderson, D. C., D, M. F. M., Fudala, P. J., Twumasi‐Ankrah, P., Kouassi, A., & Heidbreder, C. A. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000479 · Cited by 53
A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers
Silverman, B. L., Martin, W. F., Memişoğlu, A., DiPetrillo, L., Correll, C. U., & Kane, J. M. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.10.014 · Cited by 52
Effects of high intensity interval training among overweight individuals with psychotic disorders: A randomized controlled trial
Romain, A. J., Fankam, C., Karelis, A. D., Letendre, E., Mikolajczak, G., Stip, É., & Abdel‐Baki, A. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.12.021 · Cited by 52
A Decade of Organs-on-a-Chip Emulating Human Physiology at the Microscale: A Critical Status Report on Progress in Toxicology and Pharmacology
Rothbauer, M., Bachmann, B., Eilenberger, C., Kratz, S. R. A., Spitz, S., Höll, G., & Ertl, P. (2021) · Micromachines · doi:10.3390/mi12050470 · Cited by 53
Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges
Haddad, P. M., & Correll, C. U. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2181073 · Cited by 58
Switching Antipsychotic Medications to Reduce Adverse Event Burden in Schizophrenia: Establishing Evidence-Based Practice
Newcomer, J. W., Weiden, P. J., & Buchanan, R. W. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12028ah1 · Cited by 51
Pharmacogenetics of Olanzapine Metabolism
Söderberg, M. M., & Dahl, M. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.120 · Cited by 50
Mortality Risk Associated With Long-acting Injectable Antipsychotics: A Systematic Review and Meta-analyses of Randomized Controlled Trials
Kishi, T., Matsunaga, S., & Iwata, N. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw043 · Cited by 54
Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study
Morlán-Coarasa, M. J., Arias, M., de la Foz, V. O., Martínez‐García, O., Alonso-Martín, C., Crespo, J., Romero‐Gómez, M., Fábrega, E., & Crespo‐Facorro, B. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4422-7 · Cited by 50
Hippocampal volume and vasculature before and after exercise in treatment-resistant schizophrenia
Woodward, M. L., Gicas, K. M., Warburton, D. E. R., White, R. F., Rauscher, A., Leonova, O., Su, W., Smith, G. N., Thornton, A. E., Vertinsky, A. T., et al. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.06.054 · Cited by 48

Authors: De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U.
Affiliations: KU Leuven (BE)
Zucker Hillside Hospital (US)
ORCID: Detraux, Johan
Correll, Christoph U.
Venue: Nature Reviews Endocrinology
Publisher: Springer Science and Business Media LLC
Published: 2011-10-18
Volume: 8
Issue: 2
Pages: 114-126
ISSN: 1759-5029 (ISSN-L)
1759-5037
DOI: 10.1038/nrendo.2011.156
OpenAlex: W2014026290
Cited by: 1,145
References: 131
Citations by year: 2026: 85 · 2025: 75 · 2024: 62 · 2023: 91 · 2022: 97 · 2021: 99 · 2020: 84 · 2019: 77 · 2018: 73 · 2017: 85 · 2016: 74 · 2015: 75 · 2014: 65 · 2013: 52 · 2012: 44
FWCI: 6.96
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Endocrinology (publishedVersion)
PubMed (publishedVersion)
Research Publications (Maastricht University) (submittedVersion)
Lirias (KU Leuven) (submittedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
Keywords: antipsychotic drugs, type 2 diabetes, cardiovascular disease, metabolic side effects, obesity, hyperglycemia, dyslipidemia, metabolic syndrome, QT prolongation, sudden cardiac death, glucose metabolism, lipid metabolism, health care disparities, screening and monitoring
MeSH terms: Adult, Cardiovascular Diseases, Child, Diabetes Mellitus, Humans, Metabolic Diseases, Antipsychotic Agents, Weight Gain, Death, Sudden, Cardiac

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks